Class Action Announcement for SAVA Investors: A Securities Fraud Class Action Lawsuit Was Filed Against Cassava Sciences, Inc. (SAVA) - Contact Kessler Topaz Meltzer & Check, LLP

Lawsuit Overview - A securities class action lawsuit has been filed against Cassava Sciences Inc (NASDAQ: SAVA) in the United States District Court for the Western District of Texas [1] - The lawsuit is on behalf of investors who purchased or acquired Cassava securities between February 7, 2024, and November 24, 2024 [1] - The lead plaintiff deadline is February 10, 2025 [1] Allegations Against Cassava Sciences - Defendants allegedly made materially false and/or misleading statements during the Class Period [3] - Defendants failed to disclose material adverse facts about the company's business, operations, and prospects [3] - Specifically, Cassava's drug simufilam was not capable of abating the progression of Alzheimer's Disease, even in mild to moderate cases [3] - As a result, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis [3] Lead Plaintiff Process - Cassava investors may seek to be appointed as a lead plaintiff representative of the class no later than February 10, 2025 [4] - The lead plaintiff is usually the investor or small group of investors with the largest financial interest who are also adequate and typical of the proposed class [4] - The lead plaintiff selects counsel to represent the lead plaintiff and the class [4] - Investors' ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff [4] Law Firm Information - Kessler Topaz Meltzer & Check LLP is prosecuting the class action [5] - The firm has recovered billions of dollars for victims of fraud and other corporate misconduct [5] - The firm's goal is to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries [5]